A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC).
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2014
At a glance
- Drugs Talactoferrin alfa (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
- 19 Dec 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 19 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.